aromasil has been researched along with everolimus in 108 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 84 (77.78) | 24.3611 |
| 2020's | 24 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Burris, HA; Campone, M; Deleu, I; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Lebwohl, D; Mukhopadhyay, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Rugo, HS; Sahmoud, T; Vittori, L; Xu, Z; Yardley, D | 1 |
| Johnston, SR | 2 |
| Beaver, JA; Park, BH | 1 |
| El-Hashimy, M; Horiguchi, J; Inaji, H; Ito, Y; Iwase, H; Iwata, H; Kuroi, K; Masuda, N; Mukai, H; Nakayama, T; Noguchi, S; Noh, WC; Ohno, S; Ohsumi, S; Panneerselvam, A; Park, BW; Puttawibul, P; Rai, Y; Sahmoud, T; Srimuninnimit, V; Taran, T; Tokuda, Y | 1 |
| Baselga, J; Burris, HA; Campone, M; Eakle, J; El-Hashimy, M; Geberth, M; Gnant, M; Hadji, P; Hart, LL; Hortobagyi, GN; Iwata, H; Lebwohl, D; Mukai, H; Noguchi, S; Piccart, M; Pritchard, KI; Rao, S; Rugo, HS; Sahmoud, T; Taran, T | 1 |
| Baselga, J; Bauly, H; Beck, JT; Bennett, L; Burris, HA; Chouinard, E; Gnant, M; Hortobagyi, GN; Komorowski, A; Lebrun, F; Neven, P; Noguchi, S; Petrakova, K; Piccart, M; Pritchard, KI; Ricci, JF; Rugo, HS; Sahmoud, T; Taran, T; Young, R | 1 |
| Dhillon, S | 1 |
| Athanassiadis, I; Nicolatou-Galitis, O; Nikolaidi, A; Papadopoulou, E; Sonis, S | 1 |
| Peterson, ME | 1 |
| Arena, F; Bachelot, T; Baselga, J; Burris, HA; Campone, M; Deleu, I; El-Hashimyt, M; Gnant, M; Hart, L; Héniquez, A; Hortobagyi, GN; Melichar, B; Noguchi, S; Panneerselvam, A; Piccart, M; Pistilli, B; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Shtivelband, M; Taran, T | 1 |
| Arteaga, C; Ciruelos, E; Cortes-Funes, H; Ghanem, I; Manso, L | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Bennett, L; Burris, HA; Cahana, A; Campone, M; Gnant, M; Heng, DY; Horiguchi, J; Hortobagyi, GN; Komorowski, A; Neven, P; Noguchi, S; Nunzi, M; Piccart, M; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Taran, T; Zhang, J; Ziemiecki, R | 1 |
| Andre, F; Dieci, MV; Vicier, C | 1 |
| Arena, FP; Baselga, J; Burris, HA; Cahana, A; Campone, M; Erdkamp, F; Feng, W; Gnant, M; Harb, WA; Hortobagyi, GN; Lebwohl, D; Melichar, B; Noguchi, S; Petrakova, K; Piccart, M; Pistilli, B; Pritchard, KI; Rugo, HS; Taran, T; Yardley, DA | 1 |
| Mehta, A; Tripathy, D | 1 |
| Baselga, J; Bourgeois, H; Burris, HA; Campone, M; Csöszi, T; Dakhil, S; Gnant, M; Gonzalez Martin, A; Heng, D; Hortobagyi, GN; Ito, Y; Noguchi, S; Osborne, K; Panneerselvam, A; Piccart, M; Pritchard, KI; Puttawibul, P; Rugo, HS; Sahmoud, T; Srimuninnimit, V; Taran, T | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Beck, JT; Brechenmacher, T; Campone, M; Dakhil, S; Deleu, I; Douma, S; El-Hashimy, M; Geberth, M; Hart, L; Heng, DY; Hortobagyi, GN; Lebrun, F; Masuda, N; Melichar, B; Nunzi, M; Piccart, M; Pistilli, B; Ringeisen, F; Rugo, HS | 1 |
| Gilabert, M; Gonçalves, A; Launay, S | 1 |
| Láng, I; Rubovszky, G | 1 |
| Adunlin, G; Avancha, K; Diaby, V; Gluck, S; Lopes, G; Montero, AJ; Zeichner, SB | 1 |
| Adunlin, G; Ali, AA; Diaby, V; Tawk, R | 1 |
| de Boer, M; Lobbezoo, DJ; Smeets, RE; Tjan-Heijnen, VC; Vincent, J | 1 |
| Campone, M; Faust, E; Gao, H; Kageleiry, A; Signorovitch, JE; Yang, H; Zhang, J | 1 |
| Charalampous, P; Diamandi, M; Gkogkou, P; Ioannidis, G; Ioannou, R | 1 |
| Baselga, J; Burris, HA; Campone, M; Deleu, I; Fan, J; Feng, W; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Neven, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Provencher, L; Rugo, HS; Shtivelband, M; Taran, T; Wu, C | 1 |
| Donders, F; Kuypers, D; Neven, P; Wolter, P | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Horiguchi, J; Ito, Y; Iwata, H; Kuroi, K; Masuda, N; Mori, A; Mukai, H; Noguchi, S; Ohno, N; Tokuda, Y | 1 |
| Awada, A; Barthélémy, P; Gombos, A | 1 |
| Hortobagyi, GN | 1 |
| Bottini, A; Ciani, O; Generali, D; Jerusalem, G; Loi, S; Pusztai, L; Rognoni, C; Tarricone, R; Venturini, S | 1 |
| Hao, Y; Li, N; Lin, PL; Signorovitch, JE; Wu, EQ; Xie, J; Zhong, Y; Zhou, Z | 1 |
| Alexopoulos, A; Chatzikou, M; Georgoulias, V; Koumakis, G; Kourlaba, G; Maniadakis, N; Rapti, V; Relakis, J | 1 |
| Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
| Bilal, U; Prasad, V | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Kon, M; Sueoka, N; Tsubota, Y; Yamamoto, C; Yamamoto, D | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Goto, Y; Kimura, M; Sakiyama, K; Yoshida, T | 1 |
| Bianchetti, S; Camozzi, M; Ciruelos, EM; Conte, P; Gavila, JG; Generali, D; Jerusalem, G; Lang, I; Lorizzo, K; Mardiak, J; Mariani, G; Martin, M; Michelotti, A; Montemurro, F; Naume, B; Neven, P; Simoncini, E; Tjan-Heijnen, VC | 1 |
| Hayashi, N; Kashiwabara, K; Mukai, H; Naito, M; Niikura, N; Ota, Y; Umeda, M; Watanabe, K; Yamashita, T | 1 |
| Cortesi, E; D'Onofrio, L; Fabbri, MA; Gamucci, T; Giuliani, R; Iezzi, L; Magri, V; Mancini, ML; Marchetti, P; Mauri, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Ramponi, S; Roma, CL; Ruggeri, EM; Santini, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P | 1 |
| Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D | 1 |
| Niraula, S; Ocana, A | 1 |
| Ballatore, Z; Battelli, N; Berardi, R; Cascinu, S; De Lisa, M; Pagliacci, A; Pistelli, M | 1 |
| Baselga, J; Bhatt, T; Chandarlapaty, S; Chen, D; He, W; Hortobagyi, GN; Moynahan, ME; Patel, P; Ringeisen, F; Samoila, A; Sung, P; You, D | 1 |
| Kawaoka, T; Kimura, Y; Kubo, H; Miyahara, M; Nagano, H; Nagashima, Y; Shimizu, R; Yamamoto, S | 1 |
| Beck, JT; Chambers, MS; Dhillon, N; Glaspy, JA; Hwang, LC; Litton, JK; Mayer, IA; Meiller, TF; Nangia, C; Peguero, JA; Pluard, TJ; Rugo, HS; Sabo, JR; Seneviratne, L; Sweetman, RW | 1 |
| Cascinu, S; Depenni, R; Filieri, ME; Grizzi, G; Omarini, C; Piacentini, F | 1 |
| Bilancia, D; Cairo, G; Cazzaniga, ME; Chiuri, VE; Ciccarese, M; Cusmai, A; De Matteis, E; Fabi, A; Febbraro, A; Forcignanò, R; Giampaglia, M; Giordano, G; Giotta, F; La Verde, N; Latorre, A; Lorusso, V; Lupo, LI; Maiello, E; Morritti, M; Moscetti, L; Palmiotti, G; Petrucelli, L; Romito, S; Scavelli, C; Surico, G | 1 |
| Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L | 1 |
| Ascione, G; Barone, CA; Bighin, C; Bordonaro, R; Cazzaniga, ME; Cognetti, F; Foglietta, J; Frassoldati, A; Generali, D; Goffredo, F; Ionta, MT; Latini, L; Mafodda, A; Mariani, G; Michelotti, A; Minisini, AM; Molino, A; Montemurro, F; Nolè, F; Nuzzo, F; Piacentini, F; Piovano, P; Portera, G; Riccardi, F; Roila, F; Romito, S; Sartori, D; Schirone, A; Simoncini, EL; Testore, F; Vici, P | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, GV; Blasi, L; Campidoglio, S; Cazzaniga, ME; Ciccarese, M; Clivio, L; Cursano, MC; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Piezzo, M; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Torri, V; Turletti, A; Valerio, MR; Vici, P; Zambelli, A | 1 |
| Chlebowski, RT; Lin, EM; Pan, K | 1 |
| Assi, T; El Rassy, E; Kattan, J; Kourie, HR; Moussa, T | 1 |
| Barba, M; Botti, C; Botticelli, A; Buglioni, S; Catenaro, T; D'Onofrio, L; Di Filippo, S; di Lauro, L; Ferranti, F; Gamucci, T; Giordano, A; Iezzi, L; Marchetti, P; Maugeri-Saccà, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Sanguineti, G; Santini, D; Scinto, AF; Sergi, D; Sperati, F; Tomao, S; Vici, P | 1 |
| Chamseddine, AN; Mir, O; Paci, A; Ropert, S | 1 |
| Beliera, A; Carabantes, F; Ciruelos, E; Fernández, Y; Fonseca, R; García-Sáenz, JA; Gavilá, J; Martínez de Dueñas, E; Martínez-Jáñez, N; Murillo, L; Vidal, M | 1 |
| Kubo, H; Maeda, N; Nagano, H; Nagashima, Y; Sakamoto, K; Sato, Y; Suzuki, N; Takeda, S; Yamamoto, S | 1 |
| Itoh, Y; Makabe, H; Osaki, S; Saeki, T; Sugitani, I; Takahashi, M; Takahashi, T; Todo, M; Ueda, S | 1 |
| Arakawa, A; Horimoto, Y; Ichikawa, Y; Kobayashi, T; Okazaki, M; Saito, M; Tanabe, M; Tokuda, E | 1 |
| Chaiyakunapruk, N; Imanaka, Y; Kunisawa, S; Lertjanyakun, V | 1 |
| Blau, S; Burris, H; de Boer, RH; Ejlertsen, B; Ewertz, M; Fan, J; Hurvitz, S; Jerusalem, G; Kovalenko, E; Landherr, L; Louveau, AL; Noel-Baron, F; Özgüroglu, M; Taran, T; Yardley, DA | 1 |
| Decker, T; Distelrath, A; Fasching, PA; Hadji, P; Janni, W; Kreuzeder, J; Kurbacher, CM; Lüftner, D; Lux, MP; Marmé, F; Mundhenke, C; Muth, M; Quiering, C; Schneeweiss, A; Stoetzer, O; Taran, FA; Tesch, H | 1 |
| O'Shaughnessy, J; Royce, M; Thaddeus Beck, J | 1 |
| Barbolini, M; Bettelli, S; Caprera, C; Cascinu, S; Conte, PF; Filieri, ME; Guaitoli, G; Kaleci, S; Maiorana, A; Manfredini, S; Moscetti, L; Nasso, C; Omarini, C; Piacentini, F | 1 |
| Bruna-Muraille, C; Dejust, S; Eymard, JC; Morland, D; Papathanassiou, D; Savoye, AM; Yazbek, G | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ | 1 |
| Croes, S; de Boer, M; de Fallois, AOJ; Dercksen, MW; Geurts, SME; Ibragimova, KIE; Knapen, LM; Lobbezoo, DJA; Pepels, MJAE; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, FWPJ; Vriens, BEPJ | 1 |
| Adamo, B; Baselga, J; Brase, JC; Cheng, Y; Ciruelos, E; Galván, P; Hortobagyi, GN; Martínez, D; Nuciforo, P; Paré, L; Pascual, T; Prat, A; Vidal, M | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Eikesdal, HP; Ewertz, M; Fronth, L; Hege Aksnes, L; Ottestad, L; Rajendiran, S; Støre Blix, E | 1 |
| Adachi, Y; Andoh, M; Gondo, N; Hagiwara, S; Hattori, M; Hijioka, S; Iwata, H; Kotani, H; Mizuno, Y; Sawaki, M; Shimizu, J; Tachi, M; Tatematsu, M; Yoshimura, A; Yoshimura, K | 1 |
| Bachelot, T; Racadot, S; Visy, A | 1 |
| de Boer, M; de Jong, PC; Gerritsen, WR; Grutters, JC; Jonker, MA; Meek, B; Tol, J; van Erp, NP; van Herpen, CML; van Moorsel, C; Willemsen, AECAB | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Gulde, A; Hasanov, E; Krucke, GW; Krug, K | 1 |
| Boven, E; Dercksen, WM; Jager, A; Jansen, MPHM; Konings, IRHM; Kruger, DT; Martens, JWM; Oulad Hadj, J; Sleijfer, S | 1 |
| Bartsch, R; Egle, D; Gnant, M; Greil, R; Haslbauer, F; Helfgott, R; Hennebelle, M; Hock, K; Hubalek, M; Lang, A; Marth, C; Mraz, B; Öhler, L; Petru, E; Pfeiler, G; Redl, A; Steger, GG; Tinchon, C | 1 |
| Ciruelos, E; Conte, P; Gavila, J; Generali, D; Jerusalem, G; Lang, I; Martin, M; Martínez-Serrano, MJ; Montemurro, F; Neven, P; Perelló, MF; Tjan-Heijnen, VCG | 1 |
| Chen, PH; Ho, CL; Huang, TC; Kang, YN; Lee, CH; Lin, C; Wu, YY | 1 |
| Chiabudini, M; Decker, T; Falkenstein, J; Hagen, V; Hahn, A; Indorf, M; Klare, P; Kurbacher, CM; Maintz, C; Potthoff, K; Runkel, E; Sent, D; Söling, U; Vehling-Kaiser, U | 1 |
| Bianchi, GV; Capri, G; Corti, F; de Braud, F; Ligorio, F; Manglaviti, S; Nichetti, F; Rea, CG; Vernieri, C; Zattarin, E | 1 |
| Coudert, B; Goirand, F; Guérard, P; Macaire, P; Schmitt, A; Vaury, C | 1 |
| Beelen, KJ; Boven, E; de Valk, B; Kruger, DT; Linn, SC; Nieuwenhuis, M; Opdam, M; Sanders, J; van der Noort, V | 1 |
| Barba, M; Barchiesi, G; Krasniqi, E; Mazzotta, M; Pizzuti, L; Vici, P; Villa, A | 1 |
| Al Rabadi, L; Cook, MM; Kaempf, AJ; Mitri, ZI; Saraceni, MM; Savin, MA | 1 |
| Adachi, M; Amemiya, T; Hata, H; Hayashi, N; Kashiwabara, K; Kikawa, Y; Kondo, N; Mitsunaga, S; Mukai, H; Naito, M; Nakagami, K; Nakatsukasa, K; Niikura, N; Ota, Y; Shibuya, Y; Taniike, N; Umeda, M; Watanabe, KI; Yamanaka, T; Yamashita, T | 1 |
| Adamson, D; Bergh, J; Bogenrieder, T; Cortés, J; Crown, J; Espadero, RM; Gonçalves, A; Huang, DC; Im, SA; Jerusalem, G; Lee, KS; Lu, YS; Martínez, N; Morales, S; Neven, P; Pérez-Fidalgo, JA; Prat, A; Sablin, MP; Schlieker, L; Schmid, P | 1 |
| Apostolaki, S; Georgoulia, N; Georgoulias, V; Hatzidaki, D; Kallergi, G; Koinis, F; Kotsakis, A; Nikolaou, C; Politaki, E; Spiliotaki, M; Tsoukalas, N; Xenidis, N | 1 |
| Jeon, SY; Lee, KS; Park, IH; Sim, SH; Yang, HN | 1 |
| Abdel-Razeq, H; Adhav, A; Aksoy, S; Bowles, J; Chae, Y; Chang, YC; Cinkir, HY; Im, SA; Im, YH; Jeong, J; Karabulut, B; Kim, SB; Lee, KS; Park, BW; Slimane, K; Xue, H | 1 |
| Ajipa, O; Andre, F; Beck, JT; Blumenstein, L; Curigliano, G; Donnet, V; Fazio, N; Hubner, RA; Jhaveri, K; Lahner, H; Li, Z; Martin, M; Maur, M; Tortora, G | 1 |
| Habibi-Anbouhi, M; Mohammadi, E; Tabatabaei, M; Tafazzoli-Shadpour, M | 1 |
| Abdel-Razeq, H; Abdel-Razeq, N; Abdulelah, H; Bater, R; Inserat, B; Salam, M; Sharaf, B | 1 |
| Abraham, J; Budd, GT; Kruse, ML; LeGrand, SB; Mo, H; Montero, AJ; Moore, HCF; Renna, CE; Wang, L | 1 |
| Acikgoz, O; Akin, S; Avci, N; Basaran, G; Beypinar, I; Bilgetekin, I; Bilici, A; Cinkir, HY; Değirmenci, M; Demir, A; Dogan, M; Erdem, D; Kaplan, MA; Menekse, S; Olmez, OF; Paydas, S; Sakalar, T; Sakin, A; Sezgin Goksu, S; Tanriverdi, O; Temiz, S; Tural, D; Turan, M; Turhal, S; Turker, S; Uslu, R; Uysal, M; Yildiz, F | 1 |
| Abreu, M; Afonso, A; Ferreira, M; Moreira, I; Sousa, S | 1 |
| Joo, YY; Kang, EJ; Lee, K; Moon, SJ; Noh, E; Park, IH; Seo, JH | 1 |
| Baktash, N; Biyukov, T; Blau, S; Burris, HA; Cortes, J; Díaz-Redondo, T; García-Sáenz, JÁ; Hart, L; Jañez, NM; Joaquim, A; Lemieux, J; Massey, D; Morales, S; Neven, P; Rugo, HS; Schmid, P | 1 |
24 review(s) available for aromasil and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Everolimus; Female; Humans; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Secondary Prevention; Sirolimus; Treatment Outcome | 2013 |
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Topics: Adult; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Exanthema; Female; Humans; Hyperglycemia; Pneumonia; Sirolimus; Stomatitis; Treatment Outcome | 2013 |
Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Everolimus; Female; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
[Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
[Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer].
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Fatigue; Female; Humans; Sirolimus | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2015 |
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
Topics: Age Factors; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Female; Humans; Multicenter Studies as Topic; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Kaplan-Meier Estimate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Retreatment; Treatment Outcome | 2015 |
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Research Design; Signal Transduction; Triazoles | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Tamoxifen | 2018 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Fulvestrant; Humans; Neoplasm Grading; Network Meta-Analysis; Piperazines; Postmenopause; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2020 |
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Multicenter Studies as Topic; Neoplasm Metastasis; Patient Safety; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins c-akt; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2020 |
33 trial(s) available for aromasil and everolimus
| Article | Year |
|---|---|
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Recurrence; Sirolimus; Stomatitis; TOR Serine-Threonine Kinases | 2012 |
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Treatment Outcome | 2012 |
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Quality of Life; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Drug Administration Schedule; Everolimus; Female; Health Status; Humans; Middle Aged; Odds Ratio; Postmenopause; Proportional Hazards Models; Quality of Life; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Health Status; Humans; Immunosuppressive Agents; Middle Aged; Placebos; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Everolimus; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2013 |
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; International Agencies; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Sirolimus; Survival Rate | 2013 |
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Sirolimus | 2014 |
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Thiocarbamates; Treatment Outcome | 2014 |
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Topics: Androstadienes; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Everolimus; Female; Humans; Placebos; Sirolimus; Survival Analysis | 2014 |
[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Everolimus; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Sirolimus | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, e
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Everolimus; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus | 2016 |
Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial.
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Humans; Middle Aged; Receptors, Estrogen; Severity of Illness Index; Sodium Chloride; Stomatitis | 2016 |
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell-Free System; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; DNA, Neoplasm; Everolimus; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Mutation; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2017 |
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Topics: Administration, Topical; Aged; Androstadienes; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Drug Eruptions; Dyspnea; Everolimus; Female; Humans; Hyperglycemia; Middle Aged; Mouthwashes; Neoplasm Metastasis; Pneumonia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Stomatitis | 2017 |
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis | 2017 |
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Glucose; Body Mass Index; Breast Neoplasms; Everolimus; Fasting; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Prognosis; Treatment Outcome | 2017 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate | 2018 |
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2018 |
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Everolimus; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2019 |
A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Humans; Male; Middle Aged; Mouthwashes; Neoplasms; Prognosis; Prospective Studies; Quality of Life; Steroids; Stomatitis | 2019 |
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Incidence; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, H
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cross-Over Studies; Estrogen Receptor alpha; Everolimus; Female; Humans; Middle Aged; Patient Preference; Prognosis; Quality of Life; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2020 |
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Middle Aged; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Signal Transduction | 2020 |
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Everolimus; Female; Follow-Up Studies; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oral Health; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Stomatitis; Survival Rate | 2021 |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Management; Everolimus; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2021 |
Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; DNA Mutational Analysis; Everolimus; Female; Humans; Letrozole; Middle Aged; Mutation; Neoplasm Proteins; Piperazines; Pyridines | 2021 |
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Europe; Everolimus; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thiazoles; Treatment Outcome; United States | 2021 |
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Topics: Androstadienes; Breast Neoplasms; Everolimus; Female; Humans | 2023 |
51 other study(ies) available for aromasil and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
BOLERO-2 - will this change practice in advanced breast cancer?
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Everolimus; Female; Humans; Immunosuppressive Agents; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.
Topics: Aged; Androstadienes; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Dexamethasone; Everolimus; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Oral Ulcer; Prospective Studies; Recurrence; Sirolimus; Stomatitis; Stomatitis, Aphthous; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Exanthema; Fatigue; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Placebos; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Steroid; Sirolimus; Stomatitis; Treatment Outcome; Viscera | 2013 |
[BOLERO -- another remarkable step in treatment of breast cancer].
Topics: Adult; Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Markov Chains; Neoplasm Metastasis; Sirolimus | 2014 |
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Databases, Factual; Europe; Everolimus; Female; Humans; Models, Economic; Sirolimus | 2014 |
Radiation-recall dermatitis with the everolimus/exemestane combination ten years after adjuvant whole-breast radiotherapy.
Topics: Androstadienes; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Neoplasms, Second Primary; Radiodermatitis; Radiotherapy, Adjuvant; Sirolimus | 2014 |
Everolimus in acute kidney injury in a patient with breast cancer: a case report.
Topics: Acute Kidney Injury; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Creatinine; Drug Therapy, Combination; Everolimus; Female; Humans; Sirolimus | 2014 |
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies | 2015 |
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Greece; Humans; Middle Aged; Quality-Adjusted Life Years | 2015 |
The role of censoring on progression free survival: oncologist discretion advised.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bias; Breast Neoplasms; Data Interpretation, Statistical; Disease-Free Survival; Endpoint Determination; Everolimus; Female; Humans; Kaplan-Meier Estimate; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Time Factors; Treatment Failure | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
[Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Postmenopause; Retrospective Studies; Treatment Outcome | 2015 |
ESR1 Mutations Prevalent in Some Breast Cancers.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Congresses as Topic; Estrogen Receptor alpha; Everolimus; Female; Humans; Mutation; Treatment Outcome | 2016 |
[An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
Topics: Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Lung Diseases, Interstitial; Neoplasm Metastasis; Stomatitis; Thoracic Wall | 2016 |
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Regression Analysis; Retrospective Studies; Treatment Outcome | 2016 |
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms, Male; Cell Proliferation; Disease Progression; Disease-Free Survival; Estrogen Receptor alpha; Everolimus; Humans; Male; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2016 |
[A Case of Recurrent Breast Cancer with Bone Metastasis Successfully Treated with Everolimus and Exemestane Therapy].
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Recurrence; Treatment Outcome | 2017 |
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid.
Topics: Androstadienes; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cone-Beam Computed Tomography; Diagnosis, Differential; Everolimus; Female; Humans; Jaw Diseases; Mastectomy; Middle Aged; Osteonecrosis | 2017 |
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Stomatitis | 2017 |
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2017 |
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2 | 2017 |
Emerging combination endocrine therapies for advanced breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Everolimus; Female; Humans; Lung Neoplasms; Receptor, ErbB-2; Receptors, Estrogen | 2018 |
Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles | 2017 |
Curcumin dietary supplements and everolimus-based cancer treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Curcumin; Dietary Supplements; Everolimus; Female; Humans; Middle Aged | 2018 |
[Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer Patients].
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Endocrine System; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause | 2017 |
Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Patient Compliance; Pharmaceutical Services; Postmenopause; Quality of Life; Stomatitis; Treatment Failure | 2018 |
Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Ki-67 Antigen; Middle Aged; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptors, Estrogen; Ribosomal Protein S6 Kinases | 2018 |
Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Fulvestrant; Health Care Costs; Humans; Japan; Markov Chains; Middle Aged; Models, Economic; Postmenopause; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Toremifene | 2018 |
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA Mutational Analysis; Everolimus; Female; Genes, Neoplasm; Humans; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Prospective Studies; Retrospective Studies; Sirolimus | 2018 |
Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Diseases, Interstitial; Middle Aged; Positron Emission Tomography Computed Tomography; TOR Serine-Threonine Kinases; Tumor Burden | 2018 |
A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Middle Aged; Netherlands; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2019 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Estrogens; Everolimus; Female; Humans; Lymphatic Irradiation; Lymphocele; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Progesterone; Radiodermatitis; Radiotherapy, Intensity-Modulated; TOR Serine-Threonine Kinases | 2019 |
Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Respiratory Function Tests | 2019 |
Everolimus-induced pneumonitis: A diagnostic challenge.
Topics: Androstadienes; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Ductal, Breast; Computed Tomography Angiography; Cough; Diagnosis, Differential; Dyspnea; Everolimus; Female; Glucocorticoids; Humans; Lung Neoplasms; Methylprednisolone; Middle Aged; Pneumonia; Pneumonia, Bacterial; Pulmonary Embolism; Pulse Therapy, Drug; Radiography, Thoracic; Tomography, X-Ray Computed | 2020 |
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies | 2020 |
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Austria; Breast Neoplasms; Everolimus; Female; Humans; Postmenopause; Practice Patterns, Physicians'; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Piperazines; Pyridines | 2021 |
Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Premenopause; Progression-Free Survival | 2020 |
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Everolimus; Female; Hormones; Humans; Receptor, ErbB-2; Retrospective Studies; Sirolimus | 2021 |
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Receptor, ErbB-2; Salvage Therapy; Treatment Outcome | 2021 |
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Everolimus; Female; Humans; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Sirolimus | 2021 |
Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cytoskeleton; Everolimus; Female; Humans; Letrozole; Tumor Cells, Cultured | 2021 |
From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2022 |
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
Topics: Adolescent; Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Quality of Life; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2022 |
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Treatment Outcome; Turkey | 2022 |
Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Receptor, ErbB-2 | 2022 |
Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Receptor, ErbB-2; Retrospective Studies | 2023 |